River Road Asset Management LLC lifted its holdings in Maximus, Inc. (NYSE:MMS – Free Report) by 236.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 823,262 shares of the health services provider’s stock after acquiring an additional 578,326 shares during the quarter. River Road Asset Management LLC owned 1.51% of Maximus worth $71,064,000 as of its most recent SEC filing.
Several other institutional investors have also recently made changes to their positions in the business. Dimensional Fund Advisors LP boosted its holdings in Maximus by 5.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,965,916 shares of the health services provider’s stock valued at $169,700,000 after purchasing an additional 96,343 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Maximus by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 1,482,079 shares of the health services provider’s stock valued at $127,952,000 after buying an additional 5,130 shares during the last quarter. Boston Partners raised its stake in shares of Maximus by 47.0% during the 3rd quarter. Boston Partners now owns 966,139 shares of the health services provider’s stock valued at $88,236,000 after buying an additional 308,892 shares during the last quarter. Norges Bank acquired a new position in shares of Maximus in the 4th quarter valued at about $60,393,000. Finally, UBS Group AG lifted its holdings in shares of Maximus by 76.8% in the 4th quarter. UBS Group AG now owns 610,354 shares of the health services provider’s stock valued at $52,686,000 after buying an additional 265,095 shares during the period. Hedge funds and other institutional investors own 97.21% of the company’s stock.
Maximus Stock Down 6.2%
MMS opened at $55.72 on Friday. The company has a fifty day moving average of $63.15 and a two-hundred day moving average of $75.10. The stock has a market capitalization of $2.93 billion, a price-to-earnings ratio of 8.34 and a beta of 0.58. Maximus, Inc. has a fifty-two week low of $56.92 and a fifty-two week high of $100.00. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.21 and a current ratio of 2.21.
Maximus Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were issued a $0.33 dividend. This represents a $1.32 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend was Friday, May 15th. Maximus’s dividend payout ratio (DPR) is presently 19.76%.
Analyst Upgrades and Downgrades
MMS has been the topic of several analyst reports. Zacks Research lowered Maximus from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. Wall Street Zen raised Maximus from a “hold” rating to a “buy” rating in a report on Saturday, June 6th. Finally, Weiss Ratings lowered Maximus from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, May 20th. Two analysts have rated the stock with a Hold rating, According to MarketBeat.com, the stock has a consensus rating of “Hold”.
Get Our Latest Report on Maximus
Maximus Company Profile
Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.
Featured Stories
- Five stocks we like better than Maximus
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Receive News & Ratings for Maximus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus and related companies with MarketBeat.com's FREE daily email newsletter.
